Analysis for Hyperlipemia Correlation with Hepatic Involvement in Systemic Lupus Erythematosus_West China Medical Journal

Authors：

1the Department of Rheumatology, West China Hospital, Sichuan University, Chengdu 610041; 2the Department of Rheumatology and Immunology, the First People’s Hospital of Yibin, Yibin Sichuan 644000, China;

Corresponding?author：

Keywords：

高脂血癥; 肝損害; 紅斑狼瘡,系統性

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的:比較伴或不伴高脂血癥的系統性紅斑狼瘡(SLE)患者的狼瘡性肝損害的構成比例,了解高脂血癥與狼瘡性肝損害的相關性。方法:收集SLE患者100例,根據高脂血癥和狼瘡性肝損害的診斷標準,將患者分為高脂血癥組,非高脂血癥組和肝損害組,非肝損害組,收集其相關臨床數據進行比較分析。結果:1高脂血癥組發生肝損害的比例高于非高脂血癥組(χ2=9.908,P=0.002);2血脂水平中甘油三酯與γGT(r=0366,P=0.000),堿性磷酸酶(r=0.241,P=0.018),強的松劑量(r=0.31,P=0.006),24h尿蛋白定量(r=0.273,P=0.007)相關;TC與24h尿蛋白定量(r=0.273,P=0.007)相關;HDL與γ谷氨酸轉肽酶(r=0.233,P=0.022),堿性磷酸酶(r=0.265,P=0.009)相關;3-SLE活動組出現高脂血癥的比例高于非活動組(χ2=6.986,P=0.008)。結論:長期的高脂血癥可導致或加重SLE患者肝功能損害,高脂血癥是狼瘡性肝損害的危險因素之一。

Citation： LI Min,YANG Min,CEN Xiaomin,et al.. Analysis for Hyperlipemia Correlation with Hepatic Involvement in Systemic Lupus Erythematosus. West China Medical Journal, 2009, 24(8): 2060-2062. doi: Copy

1.	BORBA E F, BONFA E, VINAGRE C G, et al. Chylomicron metabolism is markedly altered in systemic lupus erythematosus[J]. Arthritis Rheum,2000,43:1033-1038.
2.	王麗英,張葳.系統性紅斑狼瘡與脂代謝異常[J].中華風濕病學雜志,2004,8(8):496-499..
3.	賀巧玲.系統性紅斑狼瘡血管炎患者血漿組織因子途經抑制物的測定與意義[J].中國現代醫學雜志,1999,9(7):29.
4.	MFILLER M H, UROWITZ M B, GLADMAN D D, et al. The liver in system lupus erythematosus[J]. Q J Med,1984,211:401-409..
5.	BOMBARDIER C, G LANDMAN D D, UROWITZ M B, et al. Derivation of the SLEDAI a disease activity index for lupus patients. The Committee on Prognosis in SLE[J]. Arthritis Rheum,1992,35:630-640.
6.	沈霞,高峰,陳肖燕.調查研究脂肪肝的誘發因素[J].上海醫學檢驗雜志,1999,14(4):236.
7.	許韓師,葉任高,紀玉蓮,等.狼瘡性肝損害的臨床和免疫學特點(附32例臨床分析)[J].中國現代醫學雜志,2000,10(1):4-5..
8.	王吉耀.脂肪肝流行病普查[J].中華肝臟病雜志,2000,8(2):117-119..
9.	BORBA E F, BONFA E. Dyslipop roteinemias in systemic lupus erythematosus: influence of disease activity and anticardiolip in antibodies[J]. Lupus,1997,6(6):553-559.

1. BORBA E F, BONFA E, VINAGRE C G, et al. Chylomicron metabolism is markedly altered in systemic lupus erythematosus[J]. Arthritis Rheum,2000,43:1033-1038.
2. 王麗英,張葳.系統性紅斑狼瘡與脂代謝異常[J].中華風濕病學雜志,2004,8(8):496-499..
3. 賀巧玲.系統性紅斑狼瘡血管炎患者血漿組織因子途經抑制物的測定與意義[J].中國現代醫學雜志,1999,9(7):29.
4. MFILLER M H, UROWITZ M B, GLADMAN D D, et al. The liver in system lupus erythematosus[J]. Q J Med,1984,211:401-409..
5. BOMBARDIER C, G LANDMAN D D, UROWITZ M B, et al. Derivation of the SLEDAI a disease activity index for lupus patients. The Committee on Prognosis in SLE[J]. Arthritis Rheum,1992,35:630-640.
6. 沈霞,高峰,陳肖燕.調查研究脂肪肝的誘發因素[J].上海醫學檢驗雜志,1999,14(4):236.
7. 許韓師,葉任高,紀玉蓮,等.狼瘡性肝損害的臨床和免疫學特點(附32例臨床分析)[J].中國現代醫學雜志,2000,10(1):4-5..
8. 王吉耀.脂肪肝流行病普查[J].中華肝臟病雜志,2000,8(2):117-119..
9. BORBA E F, BONFA E. Dyslipop roteinemias in systemic lupus erythematosus: influence of disease activity and anticardiolip in antibodies[J]. Lupus,1997,6(6):553-559.

West China Medical Journal

Analysis for Hyperlipemia Correlation with Hepatic Involvement in Systemic Lupus Erythematosus

Abstract Full text Figures/Tables Video References Cited by

Format

Content